Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | ALK rearrange NRAS G13S |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| ALK rearrange NRAS G13S | lung non-small cell carcinoma | predicted - resistant | Alectinib | Case Reports/Case Series | Actionable | In a retrospective analysis of a Phase III trial (J-ALEX), Alecensa (alectinib) treatment demonstrated limited activity with a progression-free survival of 4.4 mo in a patient with non-small cell lung cancer harboring ALK rearrangement and NRAS G13S (PMID: 40912045). | 40912045 |